NextCure (NASDAQ:NXTC) announced its earnings results on Monday. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.15), Bloomberg Earnings reports. The company had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.50 million.
NASDAQ:NXTC opened at $24.90 on Thursday. The stock’s 50-day moving average is $19.08. NextCure has a 52-week low of $13.86 and a 52-week high of $27.89.
Several brokerages recently commented on NXTC. Morgan Stanley lifted their target price on shares of NextCure from $25.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday. Bank of America began coverage on shares of NextCure in a report on Tuesday, July 9th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Piper Jaffray Companies initiated coverage on shares of NextCure in a report on Monday, June 3rd. They issued an “overweight” rating and a $26.00 target price on the stock.
There is no company description available for NextCure Inc
Featured Story: How Does the Quiet Period Work?
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.